Stakeholders of Project Data Sphere authored a Sounding Board article in the New England Journal of Medicine urging the responsible sharing of cancer trial data with global researchers.
In an example of the continued push among industry, academia, government, and hospitals to share more clinical research data, stakeholders of Project Data Sphere, LLC (PDS), a non-profit initiative of the CEO Roundtable on Cancer's Life Sciences Consortium, authored a Sounding Board article in this week’s New England Journal of Medicine urging the responsible sharing of cancer trial data with global researchers. Allowing researchers direct data access, the authors say, is critical to eliminating siloes and expanding discoveries and learnings in oncology R&D for the benefit of patients.
To that end, PDS has its own open-access cancer data platform, housing a free digital library of data. The platform, launched in 2014, allows researchers to download, share, integrate, and analyze patient data, while keeping patient anonymity intact. Presently, the platform includes 72 datasets resulting from nearly 42,000 patient lives, and PDS intends to expand the data and optimize the sharing of learned resources for trial participants. The platform can be found here: www.ProjectDataSphere.org
The CEO Roundtable on Cancer, comprised of top leaders from more than 30 U.S. companies, was founded by President Bush in 2001.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.